Join your colleagues from the likes of Apexigen, Regeneron Pharmaceuticals, Genentech, Roche, Amgen, Boehringer Ingelheim and many more at the most comprehensive cell engager event, leaving no stone ...

Funding to advance proprietary T-cell engager platforms and pipeline of highly differentiated T-cell engager therapies targeting solid tumors and autoimmune diseases Financing co-led by multiple ...

Cancer immunotherapy comes in several forms, and one area of growing research interest is a type of drug called a T cell engager. These drugs bind to a cancer cell and a T cell simultaneously, ...

Advancing the Development of Novel Targets, Safe, & Effective Multi-Specific Immune Cell Engagers for Solid & Liquid Tumors in the Clinic With a whopping 7 approvals in the last two years, the field ...

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of Cullinan Therapeutics (CGEM) have risen by 31% year-to-date, yet are down 70% over the past five years. I decided to accumulate a position in the company in late December, taking advantage ...